Safety results and discontinuation rates due to adverse events (AEs) were as expected and no new safety concerns were identified. AstraZeneca noted that results from the SAVANNAH Phase II trial showed TAGRISSO plus savolitinib (300 mg twice-daily [BID]) demonstrated a clinically meaningful and durable objective response rate (ORR) in patients with EGFRm NSCLC with high levels of MET overexpression and/or amplification whose disease progressed on treatment with 1st-line TAGRISSO. Among patients screened for enrollment in SAVANNAH, an estimated 62% had tumors with MET overexpression and/or amplification, and approximately 34% met the defined high MET level cut-off. TAGRISSO plus savolitinib demonstrated a confirmed ORR of 56%, with a median duration of response (DoR) of 7.1 months. Median PFS (mPFS) was 7.4 months.